Ely Lilly, Biogen and other financial mushrooms

In between them two seems that Ely Lilly is the real deal.

Look for a moment at the short version of their research and at few numbers related to their shares.

Eli Lilly and Company (Lilly), incorporated on January 17, 1901, is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. Its products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries.
Human Pharmaceutical Products
The Company’s human pharmaceutical products include endocrinology products, neuroscience products, oncology products and cardiovascular products. The Company’s endocrinology products include Humalog, Humalog M ix 75/25 and Humalog Mix 50/50, insulin analogs for the treatment of diabetes; Humulin, human insulin of recombinant deoxyribonucleic acid (DNA) origin for the treatment of diabetes; Trajenta, for the treatment of type II diabetes; Jentadueto, which is a combination tablet of linagliptin (Trajenta) and metformin hydrochloride for use in the treatment of type II diabetes; Jardiance, which is used for the treatment of type II diabetes (approved in the United States, Europe and Japan); Trulicity for the treatment of type II diabetes (approved in the United States and Europe); Glyxambi, which is a combination tablet of linagliptin and empagliflozin (Jardiance) for the treatment of type II diabetes (approved in the United States); Forteo for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women; Evista, which is used for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Humatrope for the treatment of human growth hormone deficiency and certain pediatric growth conditions, and Axiron, which is a topical solution of testosterone, applied by underarm applicator, for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone.
The Company’s neuroscience products include Cymbalta, Zyprexa, Strattera, Prozac and Amyvid. Cymbalta is used for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia and of chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis. Zyprexa is used for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder and bipolar maintenance. The Company’s Strattera is used for the treatment of attention-deficit hyperactivity disorder. Prozac is used for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder. Amyvid is a radioactive diagnostic agent, which is used for positron emission tomography imaging of beta-amyloid neuritic plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
The Company’s oncology products include Alimta, Erbitux, Gemzar and Cyramza. Its product, Alimta, is used for the first-line treatment, in combination with another agent, of non-small cell lung cancer (NSCLC) for patients with non-squamous cell histology; for the second-line treatment of non-squamous NSCLC; monotherapy for the maintenance treatment of non-squamous NSCLC in patients, and in combination with another agent, for the treatment of malignant pleural mesothelioma. Erbitux is indicated both as a single agent and with another chemotherapy agent for the treatment of certain types of colorectal cancers. It is used as a single agent or in combination with radiation therapy for the treatment of certain types of head and neck cancers. Gemzar is used for the treatment of pancreatic cancer; in combination with other agents, for the treatment of metastatic breast cancer, NSCLC, advanced or recurrent ovarian cancer, and in the European Union (EU) for the treatment of bladder cancer. Cyramza is approved in the United States and the European Union both as a single agent and in combination with another agent for advanced or metastatic gastric cancer, and approved in the United States in combination with another agent as a second-line treatment of metastatic NSCLC.
The Company’s cardiovascular products include Cialis, Effient and ReoPro. Cialis is used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Effient is used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome, including patients undergoing angioplasty, atherectomy or stent placement. ReoPro is for use as an adjunct to PCI for the prevention of cardiac ischemic complications. And i will not speak about their animal health products.

Biogen Inc., formerly Biogen Idec Inc., incorporated on April 1, 1997, is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company's marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.
Multiple Sclerosis Products
The Company develops, manufactures and markets a number of products designed to treat patients with MS. Its MS products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI and FAMPYRA. AVONEX (interferon beta-1a) is an intramuscular injectable therapy, indicated for the treatment of patients with relapsing forms of MS. AVONEX is a recombinant form of the interferon beta protein produced in the body in response to viral infection. The principal markets for AVONEX are the United States, United Kingdom, France, Germany, Italy and Spain. PLEGRIDY (peginterferon beta-1a) is a subcutaneous injectable therapy, indicated in the United States for the treatment of relapsing forms of MS and in the European Union (E.U.) for relapsing-remitting MS (RRMS). TECFIDERA (dimethyl fumarate) is an oral therapy indicated in the United States for the treatment of relapsing forms of MS and in the EU for people with RRMS. TYSABRI (natalizumab) is a monoclonal antibody, which is a monotherapy for the treatment of relapsing forms of MS. TYSABRI is also used to treat Crohn's disease, an inflammatory disease of the intestines. The principal markets for TYSABRI in MS are the United States, the United Kingdom, France, Germany, Italy and Spain. FAMPYRA (prolonged-release fampridine tablets), is indicated for the improvement of walking ability in adult patients with MS. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. Its principal markets for FAMPRYA are France, Germany, Spain and Canada.
Hemophilia Products
The Company develops, manufactures and markets products designed to treat patients with hemophilia A and B. Its products for hemophilia A and B include ALPROLIX and ELOCTATE. ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is a recombinant deoxyribonucleic acid-derived (DNA-derived), coagulation Factor IX concentrate indicated in the United States for treatment in adults and children with hemophilia B for control and prevention of bleeding episodes, perioperative management and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ELOCTATE (Antihemophilic Factor (Recombinant), Fc Fusion Protein) is a recombinant DNA-derived, antihemophilic factor indicated in the United States for treatment in adults and children with hemophilia A for control and prevention of bleeding episodes, perioperative management and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. It collaborates with Swedish Orphan Biovitrum AB (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX.
Genentech Collaboration
The Company collaborates with Genentech, Inc. (Genentech), a wholly owned member of the Roche Group, on the development and commercialization of RITUXAN. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the United States. RITUXAN (rituximab) is a monoclonal antibody used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia (CLL) and two forms of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. GAZYVA (obinutuzumab), in combination with chlorambucil, is indicated for the treatment of patients with previously untreated CLL. FUMADERM (fumaric acid esters) is a prolonged-release tablet formulation for the treatment of adult patients with moderate to severe plaque psoriasis.
Other
The product candidate FUMADERM (fumaric acid esters) is a prolonged-release tablet formulation. FUMADERM is approved in Germany only for the treatment of adult patients with moderate to severe plaque psoriasis.
Late Stage Product Candidates
The Company's late-stage product candidates include programs in Phase III development or in registration stage. Its late-stage products include ZINBRYTA, TYSABRI, ELOCTATE, ALPROLIX, GAZYVA and ISIS-SMN. ZINBRYTA is a monoclonal antibody that is being tested in relapsing-remitting Multiple Sclerosis (RRMS). The Phase III DECIDE clinical trial demonstrated positive top-line results, which investigated ZINBRYTA as a once-monthly, subcutaneous treatment for RRMS. Results showed that ZINBRYTA was superior on the study's primary endpoint, demonstrating a statistically significant reduction in annualized relapse rates when compared to interferon beta-1a (AVONEX). The Company completed patient enrollment in a Phase III study of TYSABRI in secondary progressive Multiple Sclerosis, known as ASCEND. The study involves approximately 875 patients. The Company's product ELOCTATE, a recombinant factor VIII Fc fusion protein (rFVIIIFc), is approved by the Food and Drug Administration (FDA) for the treatment of hemophilia A. The Company has completed a Phase III clinical study that examined the efficacy, safety and pharmacokinetics of rFVIIIFc in males 12 years of age and older with severe hemophilia A and a Phase III clinical study that evaluated the efficacy and safety of rFVIIIFc in children with hemophilia A under the age of 12. The product ALPROLIX was approved by the FDA for the treatment of hemophilia B. The Company is conducting a global pediatric study, Kids B-LONG, evaluating the efficacy and safety of recombinant factor IX Fc fusion protein (rFIXFc) in children with hemophilia B under the age of 12.
The Company is conducting Phase III clinical studies in collaboration with the Roche Group for the development of the product GAZYVA, including GOYA, a study investigating the efficacy and safety of GAZYVA in combination with CHOP chemotherapy compared to RITUXAN with CHOP chemotherapy in previously untreated patients with CD20-positive diffuse large B-cell lymphoma; GALLIUM, a clinical study investigating the efficacy and safety of GAZYVA in combination with chemotherapy followed by maintenance with GAZYVA compared to RITUXAN in combination with chemotherapy followed by maintenance with RITUXAN in previously untreated patients with indolent non-Hodgkin's lymphoma, and GADOLIN, a study investigating the efficacy and safety of GAZYVA plus bendamustine compared with bendamustine alone in patients with RITUXAN-refractory, indolent non-Hodgkin's lymphoma. The Phase III GADOLIN study demonstrated positive results showing that the study met its primary endpoint early when treated with GAZYVA plus bendamustine followed by GAZYVA alone, compared to bendamustine alone.
The Company is collaboration with Isis Pharmaceuticals, Inc. (Isis), is conducting a pivotal Phase III study evaluating ISIS-SMN in infants with spinal muscular atrophy (SMA). This Phase III study, known as ENDEAR, is a randomized, double-blind, sham-procedure controlled thirteen month study in approximately 110 infants diagnosed with SMA. The study is being conducted to evaluate the efficacy and safety of a 12 milligrams dose of ISIS-SMN with a primary endpoint of survival or permanent ventilation. The Company is also conducting a pivotal Phase III study evaluating the efficacy and safety of ISIS-SMN in non-ambulatory children with SMA. This Phase 3 study, known as CHERISH, is a randomized, double-blind, sham-procedure controlled fifteen month study in approximately 120 children with SMA. The study is being conducted to evaluate the efficacy and safety of a 12 milligram dose of ISIS-SMN with a primary endpoint of a change in the Hammersmith Functional Motor Scale-Expanded, a validated method to measure changes in muscle function in patients with SMA.
The Company competes with Teva Pharmaceutical Industries Ltd., Merck KGaA, Pfizer Inc. Bayer Group, Novartis AG, Sanofi, GenMab, GlaxoSmithKline, Pharmacyclics and Janssen, Gilead, Johnson & Johnson, AbbVie, Amgen, UCB, S.A., Bristol-Myers Squibb Company, Roche Group, Baxter, Bayer and CSL Behring.

And some almost random numbers about their shares.

LLY.N on New York Stock Exchange

86.76USD
4:02pm EDT
Change (% chg)
$0.38 (+0.44%)
Prev Close
$86.38
Open
$89.01
Day's High
$89.87
Day's Low
$85.62
Volume
1,481,711
Avg. Vol
1,498,417
52-wk High
$90.17
52-wk Low
$60.14

BIIB.O on Nasdaq 

385.05USD

23 Jul 2015

Change (% chg)

$-6.69 (-1.71%)

Prev Close 

$391.74

Open 

$394.17

Day's High 

$396.23

Day's Low 

$384.51

Volume 

2,602,459

Avg. Vol 

1,668,137

52-wk High 

$480.18

52-wk Low 

$290.85
----------------------------------------------------------
Bibliography:
1.NASDAQ
2.New York Stock Exchange
3.Reuters
4.youinvest.co.uk
5.BBC.co.uk